CoChat

Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy

Chaunzwa, Tafadzwa L., Qian, Jack M., Li, Qin, Ricciuti, Biagio, Nuernberg, Leonard, Johnson, Justin W., Weiss, Jakob, Zhang, Zhongyi, MacKay, Jamie, Kagiampakis, Ioannis, Bikiel, Damian, Di Federico, Alessandro, Alessi, Joao V., Mak, Raymond H., Jacob, Etai, Awad, Mark M., Aerts, Hugo J. W. L. · 2024 · JAMA Oncology
Cited by 50

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Importance: The association between body composition (BC) and cancer outcomes is complex and incompletely understood. Previous research in non–small-cell lung cancer (NSCLC) has been limited to small, single-institution studies and yielded promising, albeit heterogeneous, results. Objectives: To evaluate the association of BC with oncologic outcomes in patients receiving immunotherapy for advanced or metastatic NSCLC. Design, Setting, and Participants: This comprehensive multicohort analysis included clinical data from cohorts receiving treatment at the Dana-Farber Brigham Cancer Center (DFBCC) who received immunotherapy given alone or in combination with chemotherapy and prospectively collected data from the phase 1/2 Study 1108 and the chemotherapy arm of the phase 3 MYSTIC trial. Baseline and follow-up computed tomography (CT) scans were collected and analyzed using deep neural networks for automatic L3 slice selection and body compartment segmentation (skeletal muscle [SM], subcutaneous adipose tissue [SAT], and visceral adipose tissue). Outcomes were compared based on baseline BC measures or their change at the first follow-up scan. The data were analyzed between July 2022 and April 2023. Main Outcomes and Measures: Hazard ratios (HRs) for the association of BC measurements with overall survival (OS) and progression-free survival (PFS). Results: A total of 1791 patients (878 women [49%]) with NSCLC were analyzed, of whom 487 (27.2%) received chemoimmunotherapy at DFBCC (DFBCC-CIO), 825 (46.1%) received ICI monotherapy at DFBCC (DFBCC-IO), 222 (12.4%) were treated with durvalumab monotherapy on Study 1108, and 257 (14.3%) were treated with chemotherapy on MYSTIC; median (IQR) ages were 65 (58-74), 66 (57-71), 65 (26-87), and 63 (30-84) years, respectively. A loss in SM mass, as indicated by a change in the L3 SM area, was associated with worse oncologic outcome across patient groups (HR, 0.59 [95% CI, 0.43-0.81] and 0.61 [95% CI, 0.47-0.79] for OS and PFS, respectively, in DFBCC-CIO; HR, 0.74 [95% CI, 0.60-0.91] for OS in DFBCC-IO; HR, 0.46 [95% CI, 0.33-0.64] and 0.47 [95% CI, 0.34-0.64] for OS and PFS, respectively, in Study 1108; HR, 0.76 [95% CI, 0.61-0.96] for PFS in the MYSTIC trial). This association was most prominent among male patients, with a nonsignificant association among female patients in the MYSTIC trial and DFBCC-CIO cohorts on Kaplan-Meier analysis. An increase of more than 5% in SAT density, as quantified by the average CT attenuation in Hounsfield units of the SAT compartment, was associated with poorer OS in 3 patient cohorts (HR, 0.61 [95% CI, 0.43-0.86] for DFBCC-CIO; HR, 0.62 [95% CI, 0.49-0.79] for DFBCC-IO; and HR, 0.56 [95% CI, 0.40-0.77] for Study 1108). The change in SAT density was also associated with PFS for DFBCC-CIO (HR, 0.73; 95% CI, 0.54-0.97). This was primarily observed in female patients on Kaplan-Meier analysis. Conclusions and Relevance: The results of this multicohort study suggest that loss in SM mass during systemic therapy for NSCLC is a marker of poor outcomes, especially in male patients. SAT density changes are also associated with prognosis, particularly in female patients. Automated CT-derived BC measurements should be considered in determining NSCLC prognosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2024.1120

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 41

  1. Maurits, 2022, Skeletal muscle radiodensity and visceral adipose tissue index are associated with survival in renal cell cancer—a multicenter population-based cohort study., Clin Nutr, 41, 131, 10.1016/j.clnu.2021.11.012 · DOI
  2. Pickhardt, 2021, Automated CT-based body composition analysis: a golden opportunity., Korean J Radiol, 22, 1934, 10.3348/kjr.2021.0775 · DOI
  3. Pickhardt, 2022, Value-added opportunistic CT screening: state of the Art., Radiology, 303, 241, 10.1148/radiol.211561 · DOI · Paper page
  4. Pickhardt, 2020, Automated CT biomarkers for opportunistic prediction of future cardiovascular events and mortality in an asymptomatic screening population: a retrospective cohort study., Lancet Digit Health, 2, e192, 10.1016/S2589-7500(20)30025-X · DOI · Paper page
  5. Rutkowski, 2020, Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study., J Immunother Cancer, 8, 8, 10.1136/jitc-2020-001117 · DOI
  6. Caan, 2018, Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer., JAMA Oncol, 4, 798, 10.1001/jamaoncol.2018.0137 · DOI · Paper page
  7. Lee, 2018, Subcutaneous fat distribution is a prognostic biomarker for men with castration resistant prostate cancer., J Urol, 200, 114, 10.1016/j.juro.2018.01.069 · DOI
  8. Brown, 2018, The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage I-III colorectal cancer: a population-based cohort study (C-SCANS)., J Cachexia Sarcopenia Muscle, 9, 664, 10.1002/jcsm.v9.4 · doi:10.1002/jcsm.v9.4
  9. De Amorim Bernstein, 2018, Body composition predictors of therapy response in patients with primary extremity soft tissue sarcomas., Acta Radiol, 59, 478, 10.1177/0284185117723370 · DOI
  10. Kazemi-Bajestani, 2016, Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes., Semin Cell Dev Biol, 54, 2, 10.1016/j.semcdb.2015.09.001 · DOI · Paper page
  11. Tisdale, 2002, Cachexia in cancer patients., Nat Rev Cancer, 2, 862, 10.1038/nrc927 · DOI · Paper page
  12. Murphy, 2010, Loss of adipose tissue and plasma phospholipids: relationship to survival in advanced cancer patients., Clin Nutr, 29, 482, 10.1016/j.clnu.2009.11.006 · DOI
  13. Sheng, 2017, Adipocytes sequester and metabolize the chemotherapeutic daunorubicin., Mol Cancer Res, 15, 1704, 10.1158/1541-7786.MCR-17-0338 · DOI
  14. Crudele, 2021, Visceral adiposity and cancer: role in pathogenesis and prognosis., Nutrients, 13, 13, 10.3390/nu13062101 · DOI
  15. Pestine, 2018, Representation of obese participants in obesity-related cancer randomized trials., Ann Oncol, 29, 1582, 10.1093/annonc/mdy138 · DOI
  16. De Baerdemaeker, 2004, Pharmacokinetics in obese patients., Contin Educ Anaesth Crit Care Pain, 4, 152, 10.1093/bjaceaccp/mkh042 · DOI · Paper page
  17. Meng, 2023, Comprehensive guidance for antibiotic dosing in obese adults: 2022 update., Pharmacotherapy, 43, 226, 10.1002/phar.v43.3 · doi:10.1002/phar.v43.3
  18. Griggs, 2021, Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline udpdate., J Clin Oncol, 39, 2037, 10.1200/JCO.21.00471 · DOI
  19. Kichenadasse, 2020, Association between body mass inhibitor therapy for advanced non–small cell lung cancer., JAMA Oncol, 6, 512, 10.1001/jamaoncol.2019.5241 · DOI · Paper page
  20. McQuade, 2023, Association of body mass index with the safety profile of nivolumab with or without ipilimumab., JAMA Oncol, 9, 102, 10.1001/jamaoncol.2022.5409 · DOI
  21. Rosenquist, 2014, Development and reproducibility of a computed tomography-based measurement for upper body subcutaneous neck fat., J Am Heart Assoc, 3, 10.1161/JAHA.114.000979 · DOI
  22. Al-Sawaf, 2023, Body composition and lung cancer-associated cachexia in TRACERx., Nat Med, 29, 846, 10.1038/s41591-023-02232-8 · DOI
  23. Degens, 2019, The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer., Lung Cancer, 133, 130, 10.1016/j.lungcan.2019.05.021 · DOI
  24. Hansen, 2021, Measurement of body composition: agreement between methods of measurement by bioimpedance and computed tomography in patients with non–small cell lung cancer., Clin Nutr ESPEN, 44, 429, 10.1016/j.clnesp.2021.04.021 · DOI
  25. Guzik, 2017, The role of infiltrating immune cells in dysfunctional adipose tissue., Cardiovasc Res, 113, 1009, 10.1093/cvr/cvx108 · DOI · Paper page
  26. Yeoh, 2015, The association between subcutaneous fat density and the propensity to store fat viscerally., J Clin Endocrinol Metab, 100, E1056, 10.1210/jc.2014-4032 · DOI
  27. Baba, 2010, CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies., J Nucl Med, 51, 246, 10.2967/jnumed.109.068775 · DOI · Paper page
  28. Yamamoto, 2020, Imaging spectrum of abnormal subcutaneous and visceral fat distribution., Insights Imaging, 11, 24, 10.1186/s13244-019-0833-4 · DOI
  29. Mracek, 2011, Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients., Br J Cancer, 104, 441, 10.1038/sj.bjc.6606083 · DOI
  30. Rosenquist, 2015, Fat quality and incident cardiovascular disease, all-cause mortality, and cancer mortality., J Clin Endocrinol Metab, 100, 227, 10.1210/jc.2013-4296 · DOI · Paper page
  31. Kapoor, 2020, Adipose tissue density on CT as a prognostic factor in patients with cancer: a systematic review., Acta Oncol, 59, 1488, 10.1080/0284186X.2020.1800087 · DOI
  32. Murphy, 2014, Adipose tissue density, a novel biomarker predicting mortality risk in older adults., J Gerontol A Biol Sci Med Sci, 69, 109, 10.1093/gerona/glt070 · DOI
  33. Blaak, 2001, Gender differences in fat metabolism., Curr Opin Clin Nutr Metab Care, 4, 499, 10.1097/00075197-200111000-00006 · DOI · Paper page
  34. Wronska, 2012, Structural and biochemical characteristics of various white adipose tissue depots., Acta Physiol (Oxf), 205, 194, 10.1111/apha.2012.205.issue-2 · doi:10.1111/apha.2012.205.issue-2
  35. Wolfs, 2010, Co-expressed immune and metabolic genes in visceral and subcutaneous adipose tissue from severely obese individuals are associated with plasma HDL and glucose levels: a microarray study., BMC Med Genomics, 3, 34, 10.1186/1755-8794-3-34 · DOI
  36. Bjørndal, 2011, Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents., J Obes, 2011, 10.1155/2011/490650 · DOI · Paper page
  37. Womersley, 1977, A comparison of the skinfold method with extent of ‘overweight’ and various weight-height relationships in the assessment of obesity., Br J Nutr, 38, 271, 10.1079/BJN19770088 · DOI · Paper page
  38. Gallagher, 1998, Muscle distribution: variations with body weight, gender, and age., Appl Radiat Isot, 49, 733, 10.1016/S0969-8043(97)00096-1 · DOI · Paper page
  39. Cortellini, 2020, Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events., Eur J Cancer, 128, 17, 10.1016/j.ejca.2019.12.031 · DOI · Paper page
  40. Duma, 2019, Sex differences in tolerability to anti–programmed cell death protein 1 therapy in patients with metastatic melanoma and non–small cell lung cancer: are we all equal?, Oncologist, 24, e1148, 10.1634/theoncologist.2019-0094 · DOI · Paper page
  41. Bridge, 2018, OR 2.0 Context-Aware Operating Theaters, Computer Assisted Robotic Endoscopy, Clinical Image-Based Procedures, and Skin Image Analysis 204–213

Cited by

See all 50

Metadata

Authors
Chaunzwa, T. L., Qian, J. M., Li, Q., Ricciuti, B., Nuernberg, L., Johnson, J. W., Weiss, J., Zhang, Z., MacKay, J., Kagiampakis, I., Bikiel, D., Di Federico, A., Alessi, J. V., Mak, R. H., Jacob, E., Awad, M. M., & Aerts, H. J. W. L.
Affiliations
  • Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts
  • Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • AstraZeneca, Cambridge, England and Waltham, Massachusetts
  • Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Venue
JAMA Oncology
Published
2024-06-01
Volume
10
Issue
6
Pages
773
ISSN
2374-2437
Cited by
50
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy. https://app.cochat.ai/papers/10.1001/jamaoncol.2024.1120
The paper
Chaunzwa, T. L., Qian, J. M., Li, Q., Ricciuti, B., Nuernberg, L., Johnson, J. W., Weiss, J., Zhang, Z., MacKay, J., Kagiampakis, I., Bikiel, D., Di Federico, A., Alessi, J. V., Mak, R. H., Jacob, E., Awad, M. M., & Aerts, H. J. W. L. (2024). Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2024.1120

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.